Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Head & Neck 1Gastrointestinal 1

Conditions

Leukemia 32Leukemia, Myeloid, Acute 20Lymphoma 19Lymphoma, Follicular 18Breast Neoplasms 18Congenital Abnormalities 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Mantle-Cell 13Lymphoma, Large-Cell, Immunoblastic 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Carcinoma, Non-Small-Cell Lung 13Hodgkin Disease 12Head and Neck Neoplasms 12Burkitt Lymphoma 12Lymphoma, Non-Hodgkin 11Colonic Neoplasms 11Multiple Myeloma 10Lung Neoplasms 10Leukemia, Myeloid, Chronic-Phase 10Squamous Cell Carcinoma of Head and Neck 9Rectal Neoplasms 9Neuroblastoma 9Melanoma 9Lymphoma, T-Cell, Cutaneous 9Colorectal Neoplasms 9Sezary Syndrome 8Sarcoma 8Myeloproliferative Disorders 8

Interventions

Rituximab 12Cyclophosphamide 12fludarabine 8dacetuzumab 7blinatumomab 6Tacrolimus 6Busulfan 6Vincristine 5Prednisone 5Etoposide 5Doxorubicin 5Bortezomib 5fludarabine phosphate 4Valganciclovir 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Epoetin Alfa 4venetoclax 3ibrutinib 3Whole-Body Irradiation 3Methotrexate 3Melphalan 3Lenalidomide 3Ganciclovir 3Everolimus 3Dexamethasone 3Darbepoetin alfa 3Alemtuzumab 3tetulomab tetraxetan lu-177 2ponatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoproliferative Disorders × Polymerase Chain Reaction × Clear all
NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡